PLX
Price
$1.47
Change
-$0.01 (-0.68%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
117.82M
48 days until earnings call
RARE
Price
$36.24
Change
-$0.12 (-0.33%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
3.43B
30 days until earnings call
Interact to see
Advertisement

PLX vs RARE

Header iconPLX vs RARE Comparison
Open Charts PLX vs RAREBanner chart's image
Protalix BioTherapeutics
Price$1.47
Change-$0.01 (-0.68%)
Volume$13.62K
Capitalization117.82M
Ultragenyx Pharmaceutical
Price$36.24
Change-$0.12 (-0.33%)
Volume$15.91K
Capitalization3.43B
PLX vs RARE Comparison Chart in %
Loading...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PLX vs. RARE commentary
Jul 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PLX is a Buy and RARE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 02, 2025
Stock price -- (PLX: $1.48 vs. RARE: $36.36)
Brand notoriety: PLX and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PLX: 79% vs. RARE: 88%
Market capitalization -- PLX: $117.82M vs. RARE: $3.43B
PLX [@Biotechnology] is valued at $117.82M. RARE’s [@Biotechnology] market capitalization is $3.43B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PLX’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • PLX’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, PLX is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PLX’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • PLX’s TA Score: 5 bullish, 3 bearish.
  • RARE’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, PLX is a better buy in the short-term than RARE.

Price Growth

PLX (@Biotechnology) experienced а +9.63% price change this week, while RARE (@Biotechnology) price change was -1.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.51%. For the same industry, the average monthly price growth was +32.88%, and the average quarterly price growth was +3.93%.

Reported Earning Dates

PLX is expected to report earnings on Aug 18, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-0.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.43B) has a higher market cap than PLX($118M). RARE YTD gains are higher at: -13.573 vs. PLX (-21.277). PLX has higher annual earnings (EBITDA): 7.16M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. PLX (34.7M). PLX has less debt than RARE: PLX (5.24M) vs RARE (38.3M). RARE has higher revenues than PLX: RARE (591M) vs PLX (59.8M).
PLXRAREPLX / RARE
Capitalization118M3.43B3%
EBITDA7.16M-449.9M-2%
Gain YTD-21.277-13.573157%
P/E Ratio29.60N/A-
Revenue59.8M591M10%
Total Cash34.7M494M7%
Total Debt5.24M38.3M14%
FUNDAMENTALS RATINGS
PLX vs RARE: Fundamental Ratings
PLX
RARE
OUTLOOK RATING
1..100
8570
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
65100
PRICE GROWTH RATING
1..100
6460
P/E GROWTH RATING
1..100
9100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PLX's Valuation (66) in the Servicestothe Health Industry industry is in the same range as RARE (79) in the Biotechnology industry. This means that PLX’s stock grew similarly to RARE’s over the last 12 months.

PLX's Profit vs Risk Rating (100) in the Servicestothe Health Industry industry is in the same range as RARE (100) in the Biotechnology industry. This means that PLX’s stock grew similarly to RARE’s over the last 12 months.

PLX's SMR Rating (65) in the Servicestothe Health Industry industry is somewhat better than the same rating for RARE (100) in the Biotechnology industry. This means that PLX’s stock grew somewhat faster than RARE’s over the last 12 months.

RARE's Price Growth Rating (60) in the Biotechnology industry is in the same range as PLX (64) in the Servicestothe Health Industry industry. This means that RARE’s stock grew similarly to PLX’s over the last 12 months.

PLX's P/E Growth Rating (9) in the Servicestothe Health Industry industry is significantly better than the same rating for RARE (100) in the Biotechnology industry. This means that PLX’s stock grew significantly faster than RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PLXRARE
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 7 days ago
76%
Declines
ODDS (%)
Bearish Trend 9 days ago
80%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
POSKX35.90N/A
N/A
PRIMECAP Odyssey Stock
NSEIX21.66N/A
N/A
Nicholas Equity Income I
JGYIX12.77N/A
N/A
JHancock Global Shareholder Yield I
MSBVX12.03N/A
N/A
Morgan Stanley American Resilience I
ICPAX6.32-0.01
-0.16%
Integrity Mid-North American Resources A

PLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PLX has been loosely correlated with IOVA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PLX jumps, then IOVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLX
1D Price
Change %
PLX100%
-3.90%
IOVA - PLX
50%
Loosely correlated
+1.78%
STOK - PLX
31%
Poorly correlated
-2.41%
ZNTL - PLX
31%
Poorly correlated
-1.69%
CPRX - PLX
31%
Poorly correlated
-0.37%
SNDX - PLX
31%
Poorly correlated
+3.60%
More